Nurix Therapeutics reported a quarterly loss of $0.81/share, slightly worse than the $0.73 Zacks Consensus estimate (vs. a $0.52 loss a year ago). The year-over-year deterioration suggests ongoing pressure on profitability despite the small miss versus expectations.
Nurix Therapeutics reported a quarterly loss of $0.81/share, slightly worse than the $0.73 Zacks Consensus estimate (vs. a $0.52 loss a year ago). The year-over-year deterioration suggests ongoing pressure on profitability despite the small miss versus expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
